Researchers identify CTLA-4 response marke...German and US researchers have found a biomarker that identifies tumours responding to CTLA-4 checkpoint blockers. more ➔
Inotrem SA raises €39m to provide POC fo...French biotech Inotrem SA raised €39m to finance Phase IIb efficacy testing of its TREM1 blocker nangibotide (Motrem) in patients with septic shock. more ➔
Ermium Therapeutics bags €6.3m in Series...Paris-based Ermium Therapeutics has completed a Series A financing to develop breakthrough auto-immune therapeutics. more ➔
Pharvaris BV raises $66m to advance oral H... Leiden-based Pharvaris BV received a cash injection that will be used to push PHA121, the very first orally administered hereditary angioedema (HAE) drug. more ➔
4BIO Ventures launches US$50m fundLondon and Boston-based 4BIO Ventures has raised US$50m to target early-stage developers of advanced therapies by means of its new 4Bio Ventures II fund. more ➔
ADC Therapeutics set to go publicAntibody drug conjugate expert ADC Therapeutics SA has filed a Registration Statement for an Initial Public Offering with the US Securities and Exchange Commission. more ➔
iStar Medical SA raises €40.1mGlucoma transplant specialist iStar Medical SA has closed a Series C finanincing round led by LSP and Gimv. more ➔
UniQure looking to raise US$200m Dutch gene therapy company UniQure has launched a US$200m stock offering on Nasdaq. more ➔
MS: Polpharma joins forces with Sandoz Polpharma Biologics SA has partnered up with Novartis subsidiary Sandoz AG to market a natalizumab biosimilar. As part of the global commercialization agreement, Polpharma Biologics will be responsible … more ➔
Boehringer and Zealand to advance obesity...German pharma company Boehringer Ingelheim said the phase II trial for candidate drug BI456906 is expected to be initiated in late 2019 triggering a €20m milestone payment to Zealand Pharma A/S. more ➔
